Nicotine e-cigarettes as a tool for smoking cessation. Read more about Nicotine e-cigarettes as a tool for smoking cessation.
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Read more about Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Read more about Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
Ensuring remote diagnostics for pathologists: an open letter to the US Congress. Read more about Ensuring remote diagnostics for pathologists: an open letter to the US Congress.
Advancing T cell-based cancer therapy with single-cell technologies. Read more about Advancing T cell-based cancer therapy with single-cell technologies.
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Read more about Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Read more about Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Read more about Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Read more about Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
HLA-independent T cell receptors for targeting tumors with low antigen density. Read more about HLA-independent T cell receptors for targeting tumors with low antigen density.
